Thoracic vascular stent grafts market will maintain steady growth from 2025 until 2035 because of higher rates of thoracic aortic aneurysm observations as well as innovative endovascular repair processes and expanding adoption of minimal invasive surgical approaches. Thoracic stent grafts serve as essential medical tools for complex vascular treatment because they strengthen weak aortic areas while decreasing the chance of tissue rupture.
The market for thoracic aortic disease diagnosis will increase at a compound annual growth rate (CAGR) of 3.8% from USD 213 million in 2025 to USD 309.4 million by 2035 because of older population demographics and better diagnostic testing that results in earlier disease detection.
Endovascular stent grafts deliver better outcomes than open surgery because they reduce operative risks as well as shorten hospital stays and speed up patient recovery times. Projection data shows that thoracic endovascular aortic repair (TEVAR) procedures will drive medical demand because they enable safe treatment of patients who cannot undergo conventional open surgery.
New designs in stents that include branched and fenestrated grafts increase both the number of patients who can be treated and lead to better procedural results. Thoracic stent graft technology continues to improve the complex aortic disease management practices of vascular centers and hospitals.
Key Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 213 million |
| Industry Value (2035F) | USD 309.4 million |
| CAGR (2025 to 2035) | 3.8% |
Explore FMI!
Book a free demo
North America is leading the market on the various fronts, including advanced infrastructure for cardiovascular care, early adoption of TEVAR procedures, and very high prevalence rates for thoracic aortic diseases. Here, in the USA and Canada, access to minimally invasive vascular repair procedures is being expanded to both academic hospitals and community-based centers.
In Europe, steady growth is being seen, with Germany, France, and the UK being among the countries promoting early diagnosis and management of thoracic aneurysms in structured screening and surgical programs. Increasing usage proficiency coupled with wider acceptance of hybrid operating rooms are spearheading the enlargement of the market.
Asia-Pacific has become an emergent sector with enhanced vascular surgery-related infrastructure and increased awareness of aortic conditions. Developmental access to healthcare in China, Japan, and South Korea is continuing to fuel the demand for thoracic stent grafts in both public and private institutions as the adoption of endovascular technology increases.
Procedural Risk and High Device Cost
Risk associated with thoracic endovascular aortic repair (TEVAR) are not only few but also high costs for stent graft devices as they have made it difficult for thoracic vascular stent grafts markets in developing.
Some procedures are similar and sometimes regarded as emergent interventions conducted to address thoracic aortic aneurysms and dissections due to its need for a highly precise anatomical fit. Advanced imaging techniques and training vascular surgeons of a high caliber are essential for such procedures.
The post-procedural complications-including but not limited to-organ failure, endoleak, and spinal cord ischaemia-are further impediments to the extended use of TEVAR in countries. Besides that, it further restricts access due to reimbursement challenges and budget limitations in poor and middle-income countries. Above all, this just stops and slows down really next to being an innovative and commercialization work for the next generation stent grafts within a very narrowly defined specialty, high-risk area.
Minimally Invasive Adoption and Aging Population Trends
Despite the complexity, thoracic vascular stent grafts are getting bigger since the path to minimally invasive vascular repair made toward this pervading incidence of aortic diseases in aging populations. TEVAR provides less perioperative risk, faster recovery times, and shorter hospital stays than open surgery.
Improvements in device flexibility, customization, and branched stent graft designs are opening doors for this patient population, including those with complicated anatomy and high risk. As imaging precision and navigation continue to develop with the delivery system, thoracic stent grafts are really coming in for trauma, aneurysms, and management of dissections-hybrid operating rooms and very large cardiac centers.
From the year 2020 to 2024, there was market growth primarily by and large in the favour of TEVAR, along with an increase in high-risk surgical patients using TEVAR owing to improved imaging techniques and delivery of devices. Previously commercialized stent grafts remained limited in design flexibility and have been used generally for elective aneurysm repairs.
From 2025 to 2035, it will be about custom and branched thoracic stent grafts fully integrating AI-driven procedural planning, real-time intraoperative imaging, and bioengineered graft materials. This will further the expansion of endovascular training programs that will proliferate rapidly across the globe in addition to the growing public awareness of aortic diseases, and this will also prop up access and volume in procedures, especially in emerging markets with improving cardiovascular infrastructure.
Market Shifts: Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Factor | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Focused on safety and durability in high-risk patient populations. |
| Technological Advancements | Use of off-the-shelf stent grafts and CT-based sizing. |
| Sustainability Trends | Limited recycling and high-waste packaging in surgical systems. |
| Market Competition | Led by vascular device manufacturers and cardiovascular firms. |
| Industry Adoption | Common in trauma centers and cardiac surgery hospitals. |
| Consumer Preferences | Focused on reduced invasiveness and fast recovery. |
| Market Growth Drivers | Boosted by aging demographics and complex aortic pathology rates. |
| Market Factor | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Expansion to AI-assisted graft design approvals and post-market outcome tracking mandates. |
| Technological Advancements | Rise of 3D-printed, branched, and fenestrated grafts with real-time navigation integration. |
| Sustainability Trends | Shift toward bioengineered graft materials and reduced-waste procedural kits. |
| Market Competition | Entry of precision medicine companies and AI-driven surgical planning platform providers. |
| Industry Adoption | Expands to hybrid ORs, outpatient vascular labs, and emerging cardiac care networks. |
| Consumer Preferences | Shift to fully personalized vascular repair, outcome predictability, and lifelong device monitoring. |
| Market Growth Drivers | Accelerated by endovascular innovations, global access to TEVAR, and procedural digitization. |
The thoracic vascular stent grafts market is growing progressively over time in the United States, due primarily to the increase of the number of patients with thoracic aortic aneurysms, favorable reimbursement policies, and the increase in the number of patients undergoing thoracic endovascular aortic repair (TEVAR) procedures for high-risk patients.
In the United States, most hospitals have installed next-generation stent graft systems that feature improved flexibility, customizability, and delivery precision in complicated cases of the anatomy. These clinical trials and FDA approvals continue to emerge for the introduction of branched and fenestrated designs.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 3.6% |
The NHS's endorsement for interventional vascular services with regard to aortic disease support the market in the UK. The move toward TEVAR from open surgery on thoracic aortic aneurysms increases in age and high-risk patients.
Trust in repositionable, low-profile stent grafts specifically designed for tortuous anatomies and rapid deployment is increasing among clinicians.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 3.5% |
The EU presents a stable and innovative market for thoracic vascular stent grafts particularly in Germany, France and Italy. TEVAR performed in EU centers of excellence is rising because of training programs and integrated vascular teams at these establishments.
Manufacturers are producing CE-marked stent grafts with branched configurations and pliability as to anatomical differences among patients treated at these high-volume centers.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 3.8% |
Japan’s market for thoracic vascular stent grafts is growing moderately due to a rapidly aging population and a high burden of cardiovascular disease. Japanese hospitals are early adopters of advanced imaging and navigation technologies that enhance procedural accuracy in TEVAR.
Domestic and global suppliers are offering compact, trackable grafts compatible with Japan’s preference for minimally invasive techniques and long-term outcome reliability.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 3.7% |
South Korea is aspiring to a very good growth record in this market as a result of the modernizing cardiovascular care infrastructure and growing acceptance of endovascular therapies. Top-tier hospitals are now using thoracic grafts that have been enhanced to yield better radial forces and repositionability, as they are required for interventions, both elective and emergency.
South Korean vascular surgeons are working together with device developers to improve graft delivery precision and accelerate patient recovery.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 4.0% |
The thoracic vascular stent grafts market is growing as healthcare service providers use minimally invasive methods to treat thoracic aortic aneurysms, dissections, and traumatic injuries. Stent grafts present lifesaving options for patients at high surgical risk with the durability and accuracy of placement to stabilize weakened blood vessels in the thoracic region. Among product type categories, metal thoracic vascular stent grafts dominate the marketplace based on their higher compatibility with endovascular systems as well as structural integrity.
On the usage environment aspect, the largest share of the end-use will come from hospitals because they have the whole infrastructure, personnel, and immediate post-operative follow-up needed for successful stent graft deployment and recovery of patients.
Two of these segments are defining innovation and adoption in thoracic stent-graft space, as procedural vascular surgery becomes increasingly dependent on advanced interventional tools.
| Product Type | Market Share (2025) |
|---|---|
| Metal Thoracic Vascular Stent Grafts | 58.4% |
Metal thoracic vascular stent grafts are the most important product category in this segment due to their unrivalled mechanical strength and long-term reliability. These grafts can be produced from either a nitinol or a stainless steel alloy but generally provide the flexibility of conforming to the most difficult vascular anatomies while having radial force to resist vessel recoil.
Metal-based stents are what physicians prefer for high-pressure thoracic applications, where constants expansion, stability, and self-deployment have critical significance. Their design helps in the precise positioning across the aortic arch and descending aorta, minimizing the risk of migration and endoleaks.
In addition, medical device manufacturers are modifying metal stent grafts to mimic tapered diameters, fenestrated designs, and hybrid designs that all add to better technique performance in difficult anatomy. Advances also go towards improving deliverability through reducing profile size to allow smoother navigation inside dramatically tortuous vessels.
The high demand remains for durable and high performance metal stent grafts, moving toward that development in both elective and emergency vascular procedures, as TEVAR becomes established as the approach of choice for aneurysm and dissection management.
| End Use Type | Market Share (2025) |
|---|---|
| Hospitals | 62.1% |
Hospitals are the biggest end-using segment when it comes to thoracic vascular stent grafts - well-trained intervention teams, specialized facilities, and even post-operative care. Most TEVAR procedures are performed in hospitals because of the complicated anatomy of vascular structures and the need for intraoperative imaging, anesthesia services, and critical care support. Most hospitals have hybrid operating rooms for open and endovascular approaches for performing complex aortic pathologies with extreme precision and safety.
Healthcare institutions are investing more in thoracic stent grafts because of the rapidly growing population of elderly peoples and patients with other cardiovascular risk factors. Post implant imaging follow-ups are done by hospitals to check stent placement, complications, and long-term graft patency.
As procedural volumes grow, hospitals constantly acquire new-generation stent graft systems and teach doctors advanced endovascular techniques. Hospitals remain the primary focus of this segment since centralized highly specialized care outcome indeed is the key for thoracic vascular interventions.
Endovascular repair combines thoracic vascular stent grafts to create essential minimally invasive medical interventions for treating thoracic aortic aneurysms (TAA) together with dissections, traumatic transections and penetrating ulcers.
The delivery system through catheters deploys these grafts to fortify thoracic aortic areas that are weak thus minimizing rupture likelihood while shortening patient recovery times beyond traditional open surgical interventions.
The market expands due to improved imaging technologies in conjunction with aging age groups who have more aortic pathologies and hospitals adopting hybrid operating rooms for treatment procedures. Competing manufacturers focus on four areas which include device flexibility together with sealing methods and delivery system design and regulatory certifications for emergency and elective procedures.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Medtronic plc | 32-36% |
| Cook Medical Inc. | 24-28% |
| Gore Medical (W. L. Gore & Associates) | 17-21% |
| Terumo Corporation (Aortic Business) | 9-13% |
| MicroPort Scientific Corporation | 6-9% |
| Other Companies (combined) | 10-15% |
| Company Name | Key Offerings/Activities |
|---|---|
| Medtronic plc | Offers the Valiant Navion ™ and Valiant Captivia ™ stent graft systems for TEVAR procedures, featuring a low-profile delivery and active control in 2025. |
| Cook Medical Inc. | Provides Zenith Alpha™ Thoracic Endovascular Grafts with flexible delivery systems and suprarenal fixation for Zone 2 and dissection indications in 2024. |
| Gore Medical | Markets the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL system for precise deployment in tortuous thoracic anatomies in 2025. |
| Terumo Corporation | Released the RelayPro ™ and RelayPlus ™ stent graft systems for thoracic aneurysm repair with dual sheath technology and broad anatomical applicability in 2024. |
| MicroPort Scientific | Developed the Hercules™ Thoracic Stent Graft System tailored for aortic dissections, with hybrid stent designs and increasing adoption in Asia-Pacific in 2025. |
Key Company Insights
Medtronic plc
Medtronic leads the global thoracic stent graft market with the Valiant platform, offering multiple configurations for aneurysm, dissection, and traumatic injury repair. Its delivery system features precise control and repositionability, critical for challenging anatomies.
Cook Medical Inc.
Cook’s Zenith Alpha™ TEVAR system is a preferred option for low-profile access and flexibility in tortuous aortas. It supports broad clinical indications, including chronic dissection, and is backed by strong long-term patency data.
Gore Medical (W. L. Gore & Associates)
Gore’s TAG® Conformable system offers superior conformability and ease of deployment, even in Zone 0 and arch anatomies. Its ACTIVE CONTROL delivery enables staged deployment and enhanced aortic arch precision.
Terumo Corporation
Terumo’s Relay stent graft systems offer enhanced radial strength and trackability, supporting complex thoracic repairs in patients with difficult access routes. Its modular approach suits both degenerative aneurysms and traumatic lesions.
MicroPort Scientific Corporation
MicroPort provides cost-effective and anatomically adaptable thoracic stent grafts for dissection-prone aortic disease populations. Its Hercules™ system is gaining traction across China and Southeast Asia for both elective and emergency procedures.
Other Key Players (10-15% Combined)
Several specialty vascular and interventional device companies contribute to the thoracic vascular stent graft market through custom configurations, physician-modified grafts, and regional manufacturing:
The overall market size for the thoracic vascular stent grafts market was USD 213 million in 2025.
The thoracic vascular stent grafts market is expected to reach USD 309.4 million in 2035.
The increasing prevalence of thoracic aortic aneurysms, rising preference for minimally invasive endovascular procedures, and growing use of metal stent grafts in hospital-based procedures fuel the thoracic vascular stent grafts market during the forecast period.
The top 5 countries driving the development of the thoracic vascular stent grafts market are the USA, UK, European Union, Japan, and South Korea.
Metal stent grafts and hospital-based procedures lead market growth to command a significant share over the assessment period.
Thoracic Vascular Stent Grafts Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
